Clinical trials: End Stage Liver Disease
End-Stage Liver Diseases
Human Umbilical Cord-mesenchymal Stem Cells Via Different Transplantation Routes in ESLD
Stem cells are non-terminal cells that can self renew and replicate through symmetric or asymmetric division, with the potential to differentiate into different types of cells and tissues.
- Trial name
- NCT06984497
- Testing
- Infusion of umbilical cord-mesenchymal stem cells through peripheral veins, Infusion of umbilical cord-mesenchymal stem cells through hepatic artery
- Where
- China
- Volunteers
- 32 people
- Sponsor
- General Hospital of Shenyang Military Region
Cirrhosis of the Liver
HRQoL in the Low MELD Pre-tx Population
The purpose of this study is to describe the HRQoL in those with MELD scores </= 15 in a single center for those who are pre-liver transplant candidates
- Trial name
- LowMELD (NCT01573325)
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Heart Failure, Copd
Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge
The purpose of this study is to determine if medically tailored meals provided for either 2 weeks or 4 weeks (1 meal per day) to a Kaiser Permanente Colorado (KPCO) member after hospital discharge will improve their health.
- Conditions
- Heart Failure, Copd, Liver Failure, Diabetes Mellitus
- Trial name
- NCT04351880
- Testing
- Medically Tailored Meals
- Where
- 2 sites in United States
- Volunteers
- 650 people
- Sponsor
- Kaiser Permanente
Transplant-Related Disorder
Albumin, COP and Endothelial Damage in Patients With ESLD Undergoing OLT
To study the correlation between colloid osmotic pressure, albumin and the loss of vascular integrity in terms of endothelial dysfunction in patients with ESLD undergoing OLT and its impact on the perioperative course, as well as…
- Trial name
- NCT03448679
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.
Hepatocellular Carcinoma in Hepatitis C Virus Infected Patients
Application of the Stem Cell Therapy in the End Stage Liver Disease and Assessment Its Consequences in the Quality of Live Style as Well as Development of HCC.
Prospective study to calculated the incidence of hepatocellular carcinoma in hepatitis C virus infected patients after stem cell therapy.
- Trial name
- NCT01729221
- Where
- Egypt
- Volunteers
- 280 people
- Sponsor
- Cairo University
Liver Failure
Elimination of Albumin-Bound Substances by MARS and Prometheus
This trial compares the efficacy of two artificial liver support systems, MARS (Molecular Adsorbents Recirculating System) and Prometheus (FPSA, Fractionated Plasma Separation and Adsorption), in removing albumin-bound substances…
- Trial name
- NCT00407004
- Testing
- MARS (Molecular Adsorbents Recirculating System), Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Graz
End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis
Tocotrienol Against the Progression of End Stage Liver Disease
The purpose of this Phase 2 trial is to validate the outcome observed in a previous trial that oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end stage liver disease / cirrhosis.
- Conditions
- End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis, NAFLD - Nonalcoholic Fatty Liver Disease
- Trial name
- NCT02581085
- Testing
- Tocotrienol (TCT)
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Chandan Sen
Iron Deficiency Anemia, Chronic Liver Failure
Lactoferrin in Treatment of Fe Deficient Anemia In Cirrhosis
Iron deficiency and altered homeostasis due to inflammation and decreased iron utilization are main factors involved in anemia in liver disease.
- Trial name
- NCT04335058
- Testing
- Lactoferrin + Iron Supplement, Iron Supplement
- Where
- India
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
End Stage Liver Disease, Jaundice
SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury
In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury.
- Conditions
- End Stage Liver Disease, Jaundice, Liver Dysfunction, Portal Hypertension
- Trial name
- NCT06173947
- Testing
- FibroScan® Expert 630
- Where
- China
- Volunteers
- 411 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cirrhosis, Liver
Acute-On-Chronic Liver Failure In Cirrhotic Patients
Cirrhosis is a condition characterized by diffuse fibrosis, severe disruption of the intrahepatic arterial and venous flow, portal hypertension and, ultimately, liver cell failure.
- Trial name
- NCT04790435
- Where
- Egypt
- Volunteers
- 109 people
- Sponsor
- Sohag University
Acute on Chronic Liver Failure
To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase
All consecutive ACLF (Acute on Chronic Liver failure) patients presenting to the institute of liver and biliary sciences, irrespective of the etiology , who have survived the acute phase (i.e.
- Trial name
- NCT02788240
- Testing
- Peg GCSF, 20% Albumin, Nutrition
- Where
- India
- Volunteers
- 14 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Failure
Prognosis Scoring System for Acute-on-Chronic Liver Failure
This research is to establish a simple and practical system to predict the prognosis of sever hepatitis B.Seven factors (level of serum total bilirubin, prothrombin time, severity of hepatic encephalopathy, hepatorenal…
- Trial name
- NCT01961440
- Volunteers
- 1,000 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Chronic Hepatitis C, End Stage Renal Disease
Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease
The treatment response with conventional interferon alpha alone in patients with end stage renal disease and chronic hepatitis C is about 33-39%. However, the drop-out rate is 17-29.6%.
- Trial name
- NCT00172809
- Testing
- Peginterferon alfa-2a, Interferon alfa-2a
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Acute on Chronic Hepatic Failure
Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units
Patients with compensated chronic liver disease who have an episode of acute deterioration of liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate.
- Trial name
- HEPATICUS-1 (NCT01079091)
- Testing
- ADVOS (Hepa Wash), Standard Medical Therapy
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Hepa Wash GmbH
Acute-On-Chronic Liver Failure, Hepatorenal Syndrome
Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.
Acute on chronic liver failure (ACLF) is a distinct entity where, because of severe acute hepatic injury, a rapid loss of liver function develops in a patient with previous chronic liver disease(4).
- Conditions
- Acute-On-Chronic Liver Failure, Hepatorenal Syndrome, Acute Kidney Injury
- Trial name
- NCT04416282
- Testing
- Terlipressin, Albumin
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
End Stage Liver DIsease, Liver Failure
VitaSmart HOPE System: Bridge to HOPE Registry
This is a post-market, multicenter, single-arm, observational registry evaluating real-world use of the VitaSmart HOPE System under standard of care conditions.
- Trial name
- NCT07578441
- Testing
- hypothermic oxygenated perfusion therapy of a donor liver under standard of care conditions
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Bridge to Life Ltd.
End Stage Renal Disease, Hepatitis C Infection
Safety Study of the Aethlon Hemopurifier
Primary Objectives: To demonstrate the safety of the Aethlon Hemopurifier® when used in extracorporeal blood purification. Secondary Objectives: To quantify the number of viral copies captured by the Aethlon Hemopurifier® during…
- Trial name
- AEMD-IDE-20 (NCT02215902)
- Testing
- Affinity plasmapheresis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Aethlon Medical Inc.
Acute-On-Chronic Liver Failure
Platelet Transfusion in HBV-related acute-on Chronic Liver Failure
Acute-on-chronic liver failure (ACLF) is a syndrome that has recently been recognized as encompassing acute deterioration of liver function in patients with pre-existing chronic liver disease.
- Trial name
- NCT03713489
- Testing
- platelet
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cirrhosis, Intensive Care Medicine
Prognosis of Cirrhotic Patients Admitted to the General Intensive Care Unit Between 2014 and 2024: a Regional Retrospective Multicentre Cohort Study
Ten years after our team's publication, practices have changed considerably in the management of severe cirrhotic patients. This study will analyse these practices in primary care hospitals and in a tertiary centre, and assess…
- Conditions
- Cirrhosis, Intensive Care Medicine, Acute on Chronic Liver Failure(ACLF)
- Trial name
- REACIRRHOSE (NCT06948565)
- Testing
- observational study
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon